Leyden Laboratories BV added a fresh $70 million in financing to advance Panflu, its phase II-ready intranasal pan-influenza prophylactic medicine, while acquiring Cov Biotechnology Pte. Ltd. (Covbio) and its zoonotic virus-targeting portfolio to prepare for the next pandemic.
Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections.
Leyden Laboratories BV has raised $140 million in a series B financing round to develop drugs that treat whole families of viruses, including a wide-spectrum flu antibody licensed from Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit earlier this month.
DUBLIN – Last May, a quartet of Dutch biotech industry veterans gathered for a socially distanced outdoor meeting in a private garden in Leiden to discuss what could be done to prevent the present COVID-19 fiasco from ever occurring on such a scale again. A new startup, Leyden Laboratories BV, emerged from that conversation, and it has just raised €40 million (US$47.3 million) in a series A round to develop broad-spectrum, self-administered, intranasal antiviral drugs to prevent infection.
